UK Vivan Therapeutics Secures Expanded Drug Discovery & Development Platform From Mount Sinai Health System in New York

Laura Towart, CEO and Founder of Vivan Therapeutics commented, "This expanded technology license will bolster Vivan's potential as a leader in personalized cancer therapeutics discovery and development. It is an important step for the company that will enable us to have wide reaching impact on oncology and rare genetic disease therapeutics." Laura Towart, CEO and Founder of Vivan Therapeutics  commented, "This expanded technology license will bolster Vivan's potential as a leader in...

LONDON, 25/05/2021 (informazione.news - comunicati stampa - scienza e tecnologia)

 commented, "This expanded technology license will bolster Vivan's potential as a leader in personalized cancer therapeutics discovery and development. It is an important step for the company that will enable us to have wide reaching impact on oncology and rare genetic disease therapeutics."

 said, "We look forward to Vivan advancing development of this technology into therapeutics that has the potential to address cancer with an innovative, personalized and effective approach."

For more information, please contact Laura Towart / Founder & CEO of Vivan Therapeutics: laura@vivantx.com

icahn-school-of-medicine-at-mount.jpeg